Peter Verdult

Stock Analyst at Citigroup

(0.45)

# 4,193

Out of 5,090 analysts

6

Total ratings

33.33%

Success rate

-14.11%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Drug Manufacturers - Specialty & Generic Biotechnology

Stocks Rated by Peter Verdult

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	LLY Eli Lilly and Company	Maintains: Buy	$1,250 → $1,500	$1,008.56	+48.73%	4	Nov 12, 2025
	EVO Evotec SE	Upgrades: Buy	n/a	$3.13	-	1	Jun 8, 2023
	GLPG Galapagos NV	Upgrades: Buy	n/a	$31.54	-	1	Jan 27, 2022

Eli Lilly and Company

Nov 12, 2025

Maintains: Buy

Price Target: $1,250 → $1,500

Current: $1,008.56

Upside: +48.73%

Evotec SE

Jun 8, 2023

Upgrades: Buy

Price Target: n/a

Current: $3.13

Upside: -

Galapagos NV

Jan 27, 2022

Upgrades: Buy

Price Target: n/a

Current: $31.54

Upside: -